_id
6915fa42bc934aba376b26af
Ticker
SLNCF
Name
Silence Therapeutics plc
Exchange
PINK
Address
72 Hammersmith Road, London, United Kingdom, W14 8TH
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.silence-therapeutics.com
Description
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Last Close
1.6
Volume
100
Current Price
1.2
Change
-0.4
Last Updated
2026-01-07T11:55:01.385Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
153038016
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
159000
Cost Of Revenue
64000
Gross Profit
95000
Operating Expenses
26339000
Operating Income
-26244000
Interest Expense
-
Pretax Income
-20957000
Net Income
-20958000
Eps
-0.1479020936974654
Dividends Per Share
-
Shares Outstanding
141701848
Income Tax Expense
1000
EBITDA
-26088000
Operating Margin
-16505.66037735849
Total Other Income Expense Net
5287000
Cash
82031000
Short Term Investments
20161000
Receivables
22146225
Inventories
-
Total Current Assets
133632000
Property Plant Equipment
1847000
Total Assets
146790000
Payables
16967123
Short Term Debt
-85000
Long Term Debt
-
Total Liabilities
-72727000
Equity
73950220
Bs_currency_symbol
USD
Depreciation
-286000
Change In Working Capital
-2244793
Cash From Operations
-10679450
Capital Expenditures
52000
Cash From Investing
53095469
Cash From Financing
-203
Net Change In Cash
40092464
Cf_currency_symbol
USD
PE
-
PB
2.299414627840188
ROE
-28.34068647801183
ROA
-14.277539341917025
FCF
-10731450
Fcf Percent
-67.4933962264151
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
6
Net Net Investing Score
5
Quality Investing Score
2.5
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
159000
Quarters > 0 > income Statement > cost Of Revenue
64000
Quarters > 0 > income Statement > gross Profit
95000
Quarters > 0 > income Statement > operating Expenses
26339000
Quarters > 0 > income Statement > operating Income
-26244000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-20957000
Quarters > 0 > income Statement > net Income
-20958000
Quarters > 0 > income Statement > eps
-0.1479020936974654
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
141701848
Quarters > 0 > income Statement > income Tax Expense
1000
Quarters > 0 > income Statement > EBITDA
-26088000
Quarters > 0 > income Statement > operating Margin
-16505.66037735849
Quarters > 0 > income Statement > total Other Income Expense Net
5287000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
82031000
Quarters > 0 > balance Sheet > short Term Investments
20161000
Quarters > 0 > balance Sheet > receivables
22146225
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
133632000
Quarters > 0 > balance Sheet > property Plant Equipment
1847000
Quarters > 0 > balance Sheet > total Assets
146790000
Quarters > 0 > balance Sheet > payables
16967123
Quarters > 0 > balance Sheet > short Term Debt
-85000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
-72727000
Quarters > 0 > balance Sheet > equity
73950220
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
49438217
Quarters > 0 > cash Flow > depreciation
-286000
Quarters > 0 > cash Flow > change In Working Capital
-2244793
Quarters > 0 > cash Flow > cash From Operations
-10679450
Quarters > 0 > cash Flow > capital Expenditures
52000
Quarters > 0 > cash Flow > cash From Investing
53095469
Quarters > 0 > cash Flow > cash From Financing
-203
Quarters > 0 > cash Flow > net Change In Cash
40092464
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.1479020936974654
Quarters > 0 > ratios > PB
2.299414627840188
Quarters > 0 > ratios > ROE
-28.34068647801183
Quarters > 0 > ratios > ROA
-14.277539341917025
Quarters > 0 > ratios > FCF
-10731450
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-67.4933962264151
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
224000
Quarters > 1 > income Statement > cost Of Revenue
85000
Quarters > 1 > income Statement > gross Profit
139000
Quarters > 1 > income Statement > operating Expenses
24102000
Quarters > 1 > income Statement > operating Income
-23963000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-27344000
Quarters > 1 > income Statement > net Income
-27354000
Quarters > 1 > income Statement > eps
-0.19304702268793708
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
141696047
Quarters > 1 > income Statement > income Tax Expense
10000
Quarters > 1 > income Statement > EBITDA
-22491000
Quarters > 1 > income Statement > operating Margin
-10697.767857142857
Quarters > 1 > income Statement > total Other Income Expense Net
-3381000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
41739000
Quarters > 1 > balance Sheet > short Term Investments
72416000
Quarters > 1 > balance Sheet > receivables
20042000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
148553000
Quarters > 1 > balance Sheet > property Plant Equipment
1833000
Quarters > 1 > balance Sheet > total Assets
165233000
Quarters > 1 > balance Sheet > payables
14311000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
71078000
Quarters > 1 > balance Sheet > equity
94155000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-27354000
Quarters > 1 > cash Flow > depreciation
148000
Quarters > 1 > cash Flow > change In Working Capital
-4502000
Quarters > 1 > cash Flow > cash From Operations
-21784000
Quarters > 1 > cash Flow > capital Expenditures
48000
Quarters > 1 > cash Flow > cash From Investing
-1562000
Quarters > 1 > cash Flow > cash From Financing
1000
Quarters > 1 > cash Flow > net Change In Cash
-23147000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.19304702268793708
Quarters > 1 > ratios > PB
1.8059078795602996
Quarters > 1 > ratios > ROE
-29.05209494981679
Quarters > 1 > ratios > ROA
-16.554804427686964
Quarters > 1 > ratios > FCF
-21832000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-97.46428571428571
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
142000
Quarters > 2 > income Statement > cost Of Revenue
54000
Quarters > 2 > income Statement > gross Profit
88000
Quarters > 2 > income Statement > operating Expenses
28497000
Quarters > 2 > income Statement > operating Income
-28409000
Quarters > 2 > income Statement > interest Expense
11544689
Quarters > 2 > income Statement > pretax Income
-28530000
Quarters > 2 > income Statement > net Income
-28530000
Quarters > 2 > income Statement > eps
-0.20137108226842287
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
141678734
Quarters > 2 > income Statement > income Tax Expense
9562063
Quarters > 2 > income Statement > EBITDA
-19809999
Quarters > 2 > income Statement > operating Margin
-20006.338028169015
Quarters > 2 > income Statement > total Other Income Expense Net
-121000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
64886000
Quarters > 2 > balance Sheet > short Term Investments
71648000
Quarters > 2 > balance Sheet > receivables
16837000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
169790000
Quarters > 2 > balance Sheet > property Plant Equipment
1800000
Quarters > 2 > balance Sheet > total Assets
185298000
Quarters > 2 > balance Sheet > payables
18812000
Quarters > 2 > balance Sheet > short Term Debt
60000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
298041000
Quarters > 2 > balance Sheet > equity
-112743000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-28530000
Quarters > 2 > cash Flow > depreciation
138000
Quarters > 2 > cash Flow > change In Working Capital
10492000
Quarters > 2 > cash Flow > cash From Operations
-12309000
Quarters > 2 > cash Flow > capital Expenditures
4000
Quarters > 2 > cash Flow > cash From Investing
-44381000
Quarters > 2 > cash Flow > cash From Financing
14000
Quarters > 2 > cash Flow > net Change In Cash
-56444000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.20137108226842287
Quarters > 2 > ratios > PB
-1.507982586945531
Quarters > 2 > ratios > ROE
25.30534046459647
Quarters > 2 > ratios > ROA
-15.396820257099375
Quarters > 2 > ratios > FCF
-12313000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-86.71126760563381
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
24327760
Quarters > 3 > income Statement > cost Of Revenue
1606191
Quarters > 3 > income Statement > gross Profit
22721569
Quarters > 3 > income Statement > operating Expenses
25799959
Quarters > 3 > income Statement > operating Income
-3078390
Quarters > 3 > income Statement > interest Expense
11544689
Quarters > 3 > income Statement > pretax Income
23736248
Quarters > 3 > income Statement > net Income
14174185
Quarters > 3 > income Statement > eps
0.10215465086887544
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
138752224
Quarters > 3 > income Statement > income Tax Expense
9562063
Quarters > 3 > income Statement > EBITDA
7192835
Quarters > 3 > income Statement > operating Margin
-12.65381605211495
Quarters > 3 > income Statement > total Other Income Expense Net
26814638
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
121330000
Quarters > 3 > balance Sheet > short Term Investments
26004000
Quarters > 3 > balance Sheet > receivables
26908000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
187366000
Quarters > 3 > balance Sheet > property Plant Equipment
1975000
Quarters > 3 > balance Sheet > total Assets
202635000
Quarters > 3 > balance Sheet > payables
3697000
Quarters > 3 > balance Sheet > short Term Debt
117000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
68612000
Quarters > 3 > balance Sheet > equity
134023000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
22891248
Quarters > 3 > cash Flow > depreciation
119275
Quarters > 3 > cash Flow > change In Working Capital
-26323948.79
Quarters > 3 > cash Flow > cash From Operations
-24864296.44
Quarters > 3 > cash Flow > capital Expenditures
55768.29
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-8299071.97
Quarters > 3 > cash Flow > net Change In Cash
38424222
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
0.10215465086887544
Quarters > 3 > ratios > PB
1.2423439917029167
Quarters > 3 > ratios > ROE
10.575934727621378
Quarters > 3 > ratios > ROA
6.9949342413699505
Quarters > 3 > ratios > FCF
-24920064.73
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-1.0243468667070046
Quarters > 3 > health Score
60
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
43258000
Annuals > 0 > income Statement > cost Of Revenue
11810000
Annuals > 0 > income Statement > gross Profit
31448000
Annuals > 0 > income Statement > operating Expenses
94767000
Annuals > 0 > income Statement > operating Income
-63319000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-44464000
Annuals > 0 > income Statement > net Income
-45309000
Annuals > 0 > income Statement > eps
-0.326546117199534
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
138752224
Annuals > 0 > income Statement > income Tax Expense
845000
Annuals > 0 > income Statement > EBITDA
-48989000
Annuals > 0 > income Statement > operating Margin
-146.37523695039067
Annuals > 0 > income Statement > total Other Income Expense Net
18855000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
121330000
Annuals > 0 > balance Sheet > short Term Investments
26004000
Annuals > 0 > balance Sheet > receivables
26908000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
187366000
Annuals > 0 > balance Sheet > property Plant Equipment
1975000
Annuals > 0 > balance Sheet > total Assets
202635000
Annuals > 0 > balance Sheet > payables
3697000
Annuals > 0 > balance Sheet > short Term Debt
117000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
68612000
Annuals > 0 > balance Sheet > equity
134023000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-45309000
Annuals > 0 > cash Flow > depreciation
336000
Annuals > 0 > cash Flow > change In Working Capital
-33023000
Annuals > 0 > cash Flow > cash From Operations
-67640000
Annuals > 0 > cash Flow > capital Expenditures
211000
Annuals > 0 > cash Flow > cash From Investing
-21966000
Annuals > 0 > cash Flow > cash From Financing
142087000
Annuals > 0 > cash Flow > net Change In Cash
52541000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.326546117199534
Annuals > 0 > ratios > PB
1.656458655603889
Annuals > 0 > ratios > ROE
-33.80688389306313
Annuals > 0 > ratios > ROA
-22.35990820934192
Annuals > 0 > ratios > FCF
-67851000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-1.5685191178510334
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
25375000
Annuals > 1 > income Statement > cost Of Revenue
10318000
Annuals > 1 > income Statement > gross Profit
15057000
Annuals > 1 > income Statement > operating Expenses
64661000
Annuals > 1 > income Statement > operating Income
-49604000
Annuals > 1 > income Statement > interest Expense
34000
Annuals > 1 > income Statement > pretax Income
-50310000
Annuals > 1 > income Statement > net Income
-43267000
Annuals > 1 > income Statement > eps
-0.38882161098677753
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
111277251
Annuals > 1 > income Statement > income Tax Expense
-7043000
Annuals > 1 > income Statement > EBITDA
-49778000
Annuals > 1 > income Statement > operating Margin
-195.48374384236453
Annuals > 1 > income Statement > total Other Income Expense Net
-706000
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
54031000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
23977000
Annuals > 1 > balance Sheet > inventories
-18605000
Annuals > 1 > balance Sheet > total Current Assets
81021000
Annuals > 1 > balance Sheet > property Plant Equipment
1813000
Annuals > 1 > balance Sheet > total Assets
93822000
Annuals > 1 > balance Sheet > payables
2629000
Annuals > 1 > balance Sheet > short Term Debt
179000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
76772000
Annuals > 1 > balance Sheet > equity
17050000
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-50310000
Annuals > 1 > cash Flow > depreciation
498000
Annuals > 1 > cash Flow > change In Working Capital
-11662000
Annuals > 1 > cash Flow > cash From Operations
-39350000
Annuals > 1 > cash Flow > capital Expenditures
56000
Annuals > 1 > cash Flow > cash From Investing
16430000
Annuals > 1 > cash Flow > cash From Financing
25155000
Annuals > 1 > cash Flow > net Change In Cash
-785000
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-0.38882161098677753
Annuals > 1 > ratios > PB
10.44243997653959
Annuals > 1 > ratios > ROE
-253.76539589442814
Annuals > 1 > ratios > ROA
-46.11604954061947
Annuals > 1 > ratios > FCF
-39406000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.5529458128078817
Annuals > 1 > health Score
8
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
17501000
Annuals > 2 > income Statement > cost Of Revenue
10880000
Annuals > 2 > income Statement > gross Profit
8192000
Annuals > 2 > income Statement > operating Expenses
55214000
Annuals > 2 > income Statement > operating Income
-48593000
Annuals > 2 > income Statement > interest Expense
47000
Annuals > 2 > income Statement > pretax Income
-47368000
Annuals > 2 > income Statement > net Income
-40489000
Annuals > 2 > income Statement > eps
-0.41920799889738014
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
96584512
Annuals > 2 > income Statement > income Tax Expense
-6879000
Annuals > 2 > income Statement > EBITDA
-50624000
Annuals > 2 > income Statement > operating Margin
-277.6584195188846
Annuals > 2 > income Statement > total Other Income Expense Net
1225000
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
66338299
Annuals > 2 > balance Sheet > short Term Investments
19760138
Annuals > 2 > balance Sheet > receivables
20987280
Annuals > 2 > balance Sheet > inventories
-16427000
Annuals > 2 > balance Sheet > total Current Assets
117009354
Annuals > 2 > balance Sheet > property Plant Equipment
2201000
Annuals > 2 > balance Sheet > total Assets
107500000
Annuals > 2 > balance Sheet > payables
3855695
Annuals > 2 > balance Sheet > short Term Debt
446000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
85428000
Annuals > 2 > balance Sheet > equity
22072000
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-47368000
Annuals > 2 > cash Flow > depreciation
482000
Annuals > 2 > cash Flow > change In Working Capital
-8263000
Annuals > 2 > cash Flow > cash From Operations
-45456000
Annuals > 2 > cash Flow > capital Expenditures
440000
Annuals > 2 > cash Flow > cash From Investing
-16542000
Annuals > 2 > cash Flow > cash From Financing
43049000
Annuals > 2 > cash Flow > net Change In Cash
-18721000
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-0.41920799889738014
Annuals > 2 > ratios > PB
7.001414425516492
Annuals > 2 > ratios > ROE
-183.4405581732512
Annuals > 2 > ratios > ROA
-37.66418604651163
Annuals > 2 > ratios > FCF
-45896000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-2.6224787155019715
Annuals > 2 > health Score
9
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
12415000
Annuals > 3 > income Statement > cost Of Revenue
7456000
Annuals > 3 > income Statement > gross Profit
4959000
Annuals > 3 > income Statement > operating Expenses
50773000
Annuals > 3 > income Statement > operating Income
-45814000
Annuals > 3 > income Statement > interest Expense
10797
Annuals > 3 > income Statement > pretax Income
-45856000
Annuals > 3 > income Statement > net Income
-39410000
Annuals > 3 > income Statement > eps
-0.4430557010953999
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
88950441
Annuals > 3 > income Statement > income Tax Expense
-6446000
Annuals > 3 > income Statement > EBITDA
-45421000
Annuals > 3 > income Statement > operating Margin
-369.0213451469996
Annuals > 3 > income Statement > total Other Income Expense Net
-42000
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
99248252
Annuals > 3 > balance Sheet > short Term Investments
105891
Annuals > 3 > balance Sheet > receivables
331000
Annuals > 3 > balance Sheet > inventories
1
Annuals > 3 > balance Sheet > total Current Assets
86333000
Annuals > 3 > balance Sheet > property Plant Equipment
1944000
Annuals > 3 > balance Sheet > total Assets
96194000
Annuals > 3 > balance Sheet > payables
4065000
Annuals > 3 > balance Sheet > short Term Debt
137000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
87668000
Annuals > 3 > balance Sheet > equity
11507004
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-45856000
Annuals > 3 > cash Flow > depreciation
427000
Annuals > 3 > cash Flow > change In Working Capital
38845000
Annuals > 3 > cash Flow > cash From Operations
6806000
Annuals > 3 > cash Flow > capital Expenditures
1334000
Annuals > 3 > cash Flow > cash From Investing
8676000
Annuals > 3 > cash Flow > cash From Financing
30711000
Annuals > 3 > cash Flow > net Change In Cash
46088000
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-0.4430557010953999
Annuals > 3 > ratios > PB
12.3681807705985
Annuals > 3 > ratios > ROE
-342.48706266201003
Annuals > 3 > ratios > ROA
-40.96929122398487
Annuals > 3 > ratios > FCF
5472000
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
0.44075714861055176
Annuals > 3 > health Score
28
Valuation > metrics > PE
-0.1479020936974654
Valuation > metrics > PB
2.299414627840188
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-28.34068647801183
Profitability > metrics > ROA
-15.683369252873563
Profitability > metrics > Net Margin
-131.81132075471697
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
-0.9834588727389858
Risk > metrics > Interest Coverage
-5.114792438121224
Risk > final Score
40
Risk > verdict
High
Liquidity > metrics > Current Ratio
7.9155921325771645
Liquidity > metrics > Quick Ratio
7.9155921325771645
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
50
Prev Valuations > 2
100
Prev Profitabilities > 0
0
Prev Profitabilities > 1
40
Prev Profitabilities > 2
74
Prev Risks > 0
28
Prev Risks > 1
20
Prev Risks > 2
47
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:34:57.194Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-09-30
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.1479
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-06-30
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.193
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-08
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.15
Earnings History > 2 > eps Estimate
-0.11
Earnings History > 2 > eps Difference
-0.04
Earnings History > 2 > surprise Percent
-36.3636
Earnings History > 3 > period
2024-09-30
Earnings History > 3 > report Date
2024-11-14
Earnings History > 3 > date
2024-09-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
GBP
Earnings History > 3 > eps Actual
-0.19
Earnings History > 3 > eps Estimate
-0.11
Earnings History > 3 > eps Difference
-0.08
Earnings History > 3 > surprise Percent
-72.7273
Earnings History > 4 > period
2024-06-30
Earnings History > 4 > report Date
2024-06-30
Earnings History > 4 > date
2024-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
GBP
Earnings History > 4 > eps Actual
-0.111
Earnings History > 4 > eps Estimate
-0.06
Earnings History > 4 > eps Difference
-0.051
Earnings History > 4 > surprise Percent
-85
Earnings History > 5 > period
2024-03-31
Earnings History > 5 > report Date
2024-03-31
Earnings History > 5 > date
2024-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
GBP
Earnings History > 5 > eps Actual
-0.014
Earnings History > 5 > eps Estimate
-0.1
Earnings History > 5 > eps Difference
0.086
Earnings History > 5 > surprise Percent
86
Earnings History > 6 > period
2023-12-31
Earnings History > 6 > report Date
2023-12-31
Earnings History > 6 > date
2023-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
GBP
Earnings History > 6 > eps Actual
-0.125
Earnings History > 6 > eps Estimate
-0.11
Earnings History > 6 > eps Difference
-0.015
Earnings History > 6 > surprise Percent
-13.6364
Earnings History > 7 > period
2023-09-30
Earnings History > 7 > report Date
2023-09-30
Earnings History > 7 > date
2023-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
GBP
Earnings History > 7 > eps Actual
-0.074
Earnings History > 7 > eps Estimate
-0.15
Earnings History > 7 > eps Difference
0.076
Earnings History > 7 > surprise Percent
50.6667
Earnings History > 8 > period
2023-06-30
Earnings History > 8 > report Date
2023-06-30
Earnings History > 8 > date
2023-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
GBP
Earnings History > 8 > eps Actual
-0.12
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-03-31
Earnings History > 9 > report Date
2023-03-31
Earnings History > 9 > date
2023-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
GBP
Earnings History > 9 > eps Actual
-0.1149
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2022-12-31
Earnings History > 10 > report Date
2023-03-15
Earnings History > 10 > date
2022-12-31
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
GBP
Earnings History > 10 > eps Actual
-0.1497
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2022-09-30
Earnings History > 11 > report Date
2022-09-30
Earnings History > 11 > date
2022-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
GBP
Earnings History > 11 > eps Actual
-0.0846
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-06-30
Earnings History > 12 > report Date
2022-06-30
Earnings History > 12 > date
2022-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
GBP
Earnings History > 12 > eps Actual
-0.1668
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2022-03-31
Earnings History > 13 > report Date
2022-03-31
Earnings History > 13 > date
2022-03-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
GBP
Earnings History > 13 > eps Actual
-0.1148
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASpotlight On Silence Therapeutics And 2 Other Promising Penny Stocks Yahoo Finance
Read more →Deep Track Capital, LP Acquires New Stake in Silence Therapeutics PLC GuruFocus
Read more →Showing 2 of 4
(Last Updated 2025-09-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Silence Therapeutics plc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.1479
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.